AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05592327 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Citric acid abutment
Description: The implant surgery will be performed by 3rd year residents of the Postgraduate Program in Periodontology at UIC, supervised by a board-certified periodontist (J.V). Under local anaesthesia, a mid crestal incision will be performed and a full thickness flap will be raised. Implants will be placed following the manufacturer's recommendations. Implant shoulder (IS) will be placed 1 mm subcrestally, and a distance of ≥ 1.5 mm from adjacent natural tooth and ≥ 3 mm between implants will be always respected. Implant stability will be measured with Ostell ISQ. Straight definitive abutments (2 mm height) will be tightened to 25 N respecting the previous randomization procedure. One of the implants will receive an antibacterial- coated abutment (citric acid), while the other implant will receive a non-coated abutment (C). A protector cap will be screwed manually. Implant sites will be sutured with polypropylene 5/0 (Prolene Ethicon, USA) by simple stitches.
Study NCT05592327 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Citric acid abutment
Description: The implant surgery will be performed by 3rd year residents of the Postgraduate Program in Periodontology at UIC, supervised by a board-certified periodontist (J.V). Under local anaesthesia, a mid crestal incision will be performed and a full thickness flap will be raised. Implants will be placed following the manufacturer's recommendations. Implant shoulder (IS) will be placed 1 mm subcrestally, and a distance of ≥ 1.5 mm from adjacent natural tooth and ≥ 3 mm between implants will be always respected. Implant stability will be measured with Ostell ISQ. Straight definitive abutments (2 mm height) will be tightened to 25 N respecting the previous randomization procedure. One of the implants will receive an antibacterial- coated abutment (citric acid), while the other implant will receive a non-coated abutment (C). A protector cap will be screwed manually. Implant sites will be sutured with polypropylene 5/0 (Prolene Ethicon, USA) by simple stitches.
Study NCT06294262 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TETRALITE
Description: Intramuscular injection of VaxigripTetra with or without LiteVax Adjuvant
Study NCT05845814 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Coformulated vibostolimab/pembrolizumab
Description: Coformulated vibostolimab/pembrolizumab (200 mg/200 mg) IV infusion
Study NCT05845814 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: EV
Description: 1.25 mg/kg IV infusion
Study NCT05773248 — intervention group
Intervention type: PROCEDURE
Intervention: ERAS protocol
Description: The main concepts of the ERAS protocol compared to standard care included the following aspects: preoperative counselling with a specially trained nurse, restrictive use of preoperative sedation, intraoperative fluid and opioid administration and drain placement, strict antiemetic prophylaxis, early mobilisation, bowel stimulation and removal of any catheters as well as early food intake. Additionally, the ERAS protocol included a 30-day telephone follow-up.
Study NCT05351671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLS-0071 (10 mg/kg intravenously every 8 hours for total of 3 doses)
Description: After challenge with inhaled LPS, subjects will receive IV infusion of RLS-0071 at 10 mg/kg every 8 hours for total of 3 doses.
Study NCT05351671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLS-0071 (loading dose of 120 mg/kg followed by 40 mg/kg every 8 hours for 2 additional doses)
Description: After challenge with inhaled LPS, subjects will receive IV infusion of RLS-0071 at a loading dose of 120 mg/kg followed by 40 mg/kg every 8 hours for 2 additional doses.
Study NCT05351671 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (saline dosed every 8 hours for a total of 3 doses)
Description: After challenge with inhaled LPS, subjects will receive IV infusion of placebo (saline) dosed every 8 hours for a total of 3 doses.
Study NCT05856643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SZ011 CAR-NK
Description: In the escalation study, the minimum initial dose was 5.0×10\^6 cells, then increased to 1.0×10\^8, 2.0×10\^8and 5.0×10\^8 cells. The infusion is given every 2 weeks.
Study NCT05845814 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: EV
Description: 1.25 mg/kg IV infusion
Study NCT05845814 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: 200 mg IV infusion
Study NCT05786209 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole-body Balm
Description: Balm will be applied to cover newborn's entire body (while avoiding the mouth, eyes, diaper area, and scalp), and gently massaged onto the skin until the balm is fully absorbed.
Study NCT05786209 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wash and Shampoo
Description: Wash and shampoo will be used to cleanse newborn baby using an in tub bathing method.
Study NCT05079529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: β-1,3/1,6-D-Glucan From Mycelia Extract of Indonesia's Ganoderma Lucidum Group
Description: Takes β-1,3/1,6-D-Glucan capsule 3 times daily for 90 days
Study NCT06549283 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal intermittent positive pressure ventilation (NIPPV) via binasal cannula during neonatal intubation
Description: Researchers applied NIPPV treatment using binasal cannulas through a mechanical ventilator during intubation.
Study NCT05079529 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group
Description: Takes placebo capsule 3 times daily for 90 days
Study NCT05232461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PrimeC-ER 748 mg
Description: PrimeC-ER is an extended release formulation of a fixed dose combination of ciprofloxacin and celecoxib
Study NCT05232461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin 750 MG
Description: Ciprofloxacin
Study NCT05232461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib 200mg
Description: Celecoxib
Study NCT05272748 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Exercise + Core Stabilization Exercise
Description: Before and after the treatment, patients' pain, postural control (static and dynamic balance), functional level and fear of falling will be evaluated. In addition to the exercises in the conventional exercise group, patients will perform pelvic tilt, lateral bridge, single leg bridge, plank, extremity exercises in the crawling position, abdominal crunch, oblique crunch, dead bug, superman exercise. Exercises will be applied 3 times a week.
Study NCT05272748 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Exercise
Description: Before and after the treatment, patients' pain, postural control (static and dynamic balance), functional level and fear of falling will be evaluated. Terminal knee extension, straight leg raise, heel slide, adductor isometric, bridge, mini squat, heel raise, lunge, range of motion and stretching exercises for lower extremities will be performed by the patients. Exercises will be applied 3 times a week.
Study NCT04954027 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: 5 visits are planned during the study :~* the inclusion visit : during this visit the patient's non-opposition is obtained and then the patient answer to self-administered questionnaires online~* 4 telephone interviews for follow-up by investigator
Study NCT06294262 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TETRALITE
Description: Intramuscular injection of VaxigripTetra with or without LiteVax Adjuvant
Study NCT05570708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDMA, LSD, psilocybin
Description: * MDMA per os (2 x 100mg) in a group setting~* LSD per os (75 and 150 mcg) in a 1:1 setting~* Psilocybin per os (15 mg and 25 mg) in a group setting~* Three study days are without drug administration: Participants experience the role of the therapist in a 1:1 setting
Study NCT04655807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64304500
Description: JNJ-64304500 will be administered as SC injection.
Study NCT04655807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered as SC injection.
Study NCT04655807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Adalimumab will be administered as SOC biological therapy.
Study NCT04655807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Ustekinumab will be administered as SOC biological therapy.
Study NCT06532526 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Predicta® Bioactive Desensitizer (PBD, PARKELL, EDGEWOOD, NY, USA)
Description: A bioactive desensitizer gel that applied on teeth to reduce tooth sensitivity associated with dental bleaching.
Study NCT06532526 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gel with 1.23% sodium fluoride (EAZIGEL, VERICOM CO., LTD. SOUTH KOREA)
Description: Fluoride gel that applied on the teeth to reduce tooth sensitivity
Study NCT06532526 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel without any active ingredients.
Description: Water-based glycerin gel is used as the Placebo gel without active ingredients
Study NCT05478512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VenObi+Ven or VenObi+VenZan
Description: Patients will receive obinutuzumab 1000mg IV (cycle 1: day 1,8,15; Cycle2-6: day1) + venetoclax 400mg/d (preceded by a ramp-up phase) until cycle 9, day 28.~At cycle9:~* if uMRD = Venetoclax 400 mg/d orally until cycle 13.~* if residual disease in the BM or PB = Venetoclax 400 mg/d + Zanubrutinib 160 mg orally twice daily until cycle 21.~then, at cycle 21:~* if uMRD = stop treatment~* if residual disease in the BM or PB = zanubrutinib 160 mg orally twice daily until disease progression
Study NCT04743297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prostaglandin E2 (Propess)
Description: Propess - The vaginal insert is removed 24 h after the application. It is only to be removed earlier in case of the onset of active labour or at the occurrence of hyperstimulation.
Study NCT04743297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prostaglandin E2 (Prostin)
Description: Prostin - 3 mg vaginal tablet is placed in the posterior vaginal fornix. Dose can be repeated every 8 hours till onset of active labour or the occurrence of hyper-stimulation.
Study NCT06348602 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine ophthalmic solution 0.1%
Description: Ophthalmic prophylaxis begins once engraftment is documented, with a dose of 1 drop in each eye every 12 hours, continued for a duration of 12 continuous months
Study NCT04207424 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Emblization of the gastro-epiploic arcade
Description: Endovascular embolization of the gastro-epiploic arcade using 300-500 micrometres calibrated polyvinyl-alcohol microparticles
Study NCT03904069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 553
Description: AMG 553 is a chimeric antigen T-cell receptor (CAR-T) therapy
Study NCT04693702 — intervention group
Intervention type: DEVICE
Intervention: Corneal treatment by a low vision aid device
Description: Near infrared light is used to irradiate the cornea to change the modulus of small volumes of anterior stroma. The modulus change produces a change in light distribution onto the retina. Light rays are redirected from dysfunctional areas of the retina to functional areas, thereby improving patient vision.
Study NCT04974905 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: retrograde access for re-canalization of infra-inguinal arterial occlusive disease
Description: after failed antegrade approach for re-canalization of infra-inguinal arterial occlusive disease( failed reentry into the distal true lumen), the retrograde approach will be attempted
Study NCT05731817 — intervention group
Intervention type: OTHER
Intervention: Observational study
Description: N/A - observational study.
Study NCT04813614 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STYLAGE M Lidocaine
Description: Injection in the lips
Study NCT04813614 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active control group
Description: Injection in the lips
Study NCT06360055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran Etexilate
Description: Subjects will receive a single oral dose of 110mg (low dose specification in the instructions) or lower of dabigatran etexilate on an empty stomach on the morning of day 1 and day 16 of the trial period.
Study NCT06360055 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: D-mannose
Description: Subjects will take 3g (1g\*3 tablets) of D-mannose tablets every morning and evening from the 2nd day to the 15th day of the trial period, with a total of 6g/day (medium dose specification in the instructions).
Study NCT06348602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus ophthalmic ointment 0.03%
Description: Ophthalmic prophylaxis begins once engraftment is documented, with a dose of approximately 1 cm or the necessary amount to cover the lower fornix, every 12 hours, continued for a duration of 12 continuous months
Study NCT05422846 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard treatment
Description: The control group will be provided with the necessary approaches for diabetic foot ulcer care and diaphragmatic breathing exercises.
Study NCT05422846 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic exercise
Description: The aerobic exercise group will be provided with the necessary approaches for diabetic foot ulcer care and in addition to diaphragmatic breathing exercises, they will be provided with aerobic exercise twice a week with a physiotherapist.
Study NCT05422846 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise protocol
Description: The protocol exercise group will be provided with the necessary approaches for diabetic foot ulcer care and exercises suitable for the physical condition of the wound and the patient, in addition to diaphragmatic breathing exercises. This group will also work with a physiotherapist twice a week.
Study NCT06300151 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound Real-time Guidance combined with Dural Puncture Epidural Labor Analgesia
Description: Ultrasound real-time guidance technology has great advantages over traditional blind exploration technology in terms of accuracy, success rate, and reduction of puncture damage in intervertebral space positioning through operational visualization, greatly improving the effectiveness and safety of spinal block.
Study NCT06300151 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dural Puncture Epidural Labor Analgesia
Description: Dural Puncture Epidural is a clinical improvement of Combined Spinal-Epidural and is widely used in Maternal. The implementation step is to complete the epidural puncture, temporarily do not place a tube, puncture the dura mater with a subarachnoid anesthesia needle, but do not directly inject drugs into the subarachnoid space, and then leave an epidural catheter for administration according to epidural block.
Study NCT05243524 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maveropepimut-S
Description: SC injection on days 7, 28, then q8w
Study NCT05243524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 50mg
Description: PO BID, one week on, one week off
Study NCT05193201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human thrombopoietin injection
Description: recombinant human thrombopoietin: 15000 U subcutaneous injection once a day for 7 days
Study NCT06230549 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adaptive Radiotherapy
Description: Adaptive Radiotherapy, online onboard adaptation of dose distribution with a specialist radiation oncologist and a medical physicist
Study NCT06230549 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Adaptive Radiotherapy
Description: Adaptive Radiotherapy, online onboard adaptation of dose distribution with a specialist radiation oncologist and a medical physicist
Study NCT05829447 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: G-EYE 760 R endoscope
Description: The G-EYE 760 endoscope consists of a standard last-generation colonoscope with a permanently integrated balloon, placed at the bending section of the endoscope, which can be gradually insufflated on-demand by the endoscopist through a pedal control. During the endoscope withdrawal the balloon flattens haustral folds, centralizes the colonoscope's optics and reduces bowel slippage, thus facilitating mucous inspection and polyp detection.
Study NCT06501547 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Leucocyte Telomere Length from blood draw
Description: blood draw, PCR method to see leucocyte telomere length
Study NCT05994924 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Handout
Description: Educational handout describing responsive feeding practices.
Study NCT05994924 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video Series
Description: Videos geared toward responsive feeding practices.
Study NCT05994924 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Discussion Sessions
Description: Group discussion following video viewing led by Imprints Cares, a community organization focused on early childhood education.
Study NCT05171309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: 250 mg once daily (QD) oral dosing.
Study NCT05171309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: 200 mg intravenously every 2 weeks.
Study NCT05171309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NK cell
Description: Cord blood derived NK cells 4 cycles, one cycle is defined as: total cells ≥1×109 per time, continuous intravenous infusion for 2 days every 14±2 days
Study NCT05282966 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: QSant-TM Urine Test
Description: QSant™ is a needle free urine test collected in-home or in-clinic to aid in the evaluation and management of kidney transplant recipients' allograft status. QSant evaluates 6 kidney-specific biomarkers.
Study NCT04737291 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: drug coated balloon
Description: use of drug coated balloon in treatment of critical limb ischemia
Study NCT06368544 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lower-body positive-pressure
Description: By increasing the chamber in the lower body around Pressure acts as a counterweight to gravity
Study NCT04959669 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DeSSBack
Description: The DeSSBack (Decision Support System for Low Back Pain) is a decision support tool developed in the University of Malaya Medical Centre's (UMMC) electronic medical record system by adopting and re-packaging the STaRT system to suit the local context. It stratifies patients with low back pain to low, medium or high risk, which are then managed differently. The DeSSBack has also been incorporated the local clinical practice guidelines and feedback from local experts.
Study NCT06308406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab； HRS-1167
Description: Bevacizumab: injection, 100mg(4mL), intravenous infusion HRS-1167: Tablets, 25mg/tablet, oral
Study NCT04881409 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respiratory support with nasal high-flow (NHF)
Description: Patient with AECOPD is treated with NHF.
Study NCT05530863 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assisted Therapy
Description: The participant will receive coaching calls and support
Study NCT05530863 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Hygiene
Description: Standard Sleep Hygiene instructions.
Study NCT05530863 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Hygiene
Description: Standard Sleep Hygiene instructions.
Study NCT04771299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cariprazine
Description: Cariprazine is a novel atypical antipsychotic medication that has been approved by the Food and Drug Administration (FDA) for treatment of schizophrenia, manic or mixed, and depressive episodes associated with bipolar I disorder.
Study NCT04771299 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is an inactive substance that looks identical to the study medication that contains no therapeutic ingredient.
Study NCT06422325 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MPC closed-loop system in insulin only mode
Description: The Model Predictive Control (MPC) insulin infusion algorithm contains a model within the controller that takes as an input the aerobic metabolic expenditure in addition to the CGM and meal in puts. The algorithm uses heart rate and accelerometer data collected on the patient's body to calculate metabolic expenditure (METs). The METs then acts on the model for the insulin dynamics, whereby more energy expenditure and longer duration exercise can lead to a more substantial effect of insulin on the CGM. The MPC also has missed meal insulin bolus detection where the system will calculate the amount of insulin that was missed for a meal. The missed meal boluses can be delivered automatically without any input from the user. This feature can also be disabled. The device in this mode will administer insulin continuously for managing blood sugar.